Skip to Main Content

Months and even years after a successful bone marrow transplant, when patients in remission finally start to see their cancer nightmare fading away, the cure can turn against them.

Immune cells from the transplant donor view the patient’s body as foreign and start attacking tissues and organs. The cancer is gone, but now patients must deal with painful mouth sores, eyes that cannot produce tears, skin rashes, immobile joints and damaged organs. The debilitating condition is called chronic graft-versus-host disease, or GVHD, and can affect as many as half of bone marrow transplant patients.


Kadmon (KDMN), the New York-based biotech, is developing the first drug designed specifically to target chronic GVHD. In new but still preliminary clinical trial results presented Sunday, the Kadmon drug, a pill called KD025, showed meaningful reductions of chronic GVHD in two-thirds of patients — nearly all of whom entered the pivotal clinical trial after current treatment options stopped working.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!